Sadhana Jackson, M.D.

Sadhana Jackson, M.D.
Assistant Clinical Investigator
Head, Developmental Therapeutics/Pharmacology Section

Dr. Jackson is an assistant clinical investigator within the Neuro-Oncology Branch (NOB).  Her research interests center on evaluating the blood-brain barrier (BBB) of malignant gliomas in an attempt to transiently disrupt the BBB by pharmacologic means in an effort to improve chemotherapy delivery.  She has experience with the use of brain microdialysis, pharmacokinetic analysis, and utilization of preclinical models to study central nervous system (CNS) pharmacology.  Dr. Jackson leads collaborative preclinical and clinical studies focused on understanding blood-brain barrier integrity in normal brain and malignant gliomas with an effort to develop novel treatment strategies for patients with brain tumors.

Areas of Expertise
1) neuro-oncology, 2) blood-brain barrier, 3) drug delivery, 4) pharmacokinetics, 5) malignant brain tumors

Contact Info

Sadhana Jackson, M.D.
Center for Cancer Research
National Cancer Institute
Building 82, Room 227
Bethesda, MD 20892
Ph: 240-760-6018
Fax: 240-541-4432

One of the major obstacles to effectively treating central nervous system (CNS) disease is the integrity of the blood-brain barrier (BBB).  The BBB prevents delivery of systemic drugs to the brain and tumor tissue.  While previous studies have focused on circumventing the BBB using direct tumor delivery, and mechanically opening the BBB, very few agents have been evaluated for effectiveness of BBB disruption in an effort to increase drug entry to the brain. 

My research area focuses on understanding the blood-brain barrier and blood-tumor barrier in malignant gliomas.  My laboratory studies pertain to comprehensive evaluation of BBB biology by analysis of the genomics, proteomics and pharmacokinetics.  These in vitro and preclinical studies assess BBB characteristics in both normal and diseased brain.  These findings will then be translated to clinical trials to evaluate the utility of varied pharmacologic agents to transiently open the BBB to improve chemotherapeutic delivery. 

Scientific Focus Areas:
Cancer Biology, Clinical Research, Molecular Pharmacology

Selected Key Publications

  1. McCord M, Mukouyama YS, Gilbert MR, Jackson S.
    Front Cell Neurosci. 2017. [ Journal Article ]
  2. Jackson S, ElAli A, Virgintino D, Gilbert MR.
    Neuro Oncol.. 19(9): 1173-1182, 2017. [ Journal Article ]
  3. Jackson S, George RT, Lodge MA, Piotrowski A, Wahl RL, Gujar SK, Grossman SA
    J Neurooncol. . 132(2): 513-519, 2017. [ Journal Article ]
  4. Jackson S, Anders NM, Mangraviti A, Wanjiku TM, Sankey EW, Liu A, Brem H, Tyler B, Rudek MA, Grossman SA.
    J Neurooncol. [Epub ahead of print - Dec. 1], 2015. [ Journal Article ]
  5. Morfouace M, Cheepala S, Jackson S, Fukuda Y, Patel YT, Fatima S, Kawauchi D, Shelat AA, Stewart CF, Sorrentino BP, Schuetz JD, Roussel MF.
    Cancer Res. 75(18): 3879-89, 2015. [ Journal Article ]

Dr. Jackson received her medical doctorate (M.D.) degree in medicine from Eastern Virginia Medical School (EVMS) in 2007.  She completed her residency at Orlando Health in pediatrics in 2010.  In 2013, she completed her pediatric hematology/oncology fellowship at St. Jude Children’s Hospital (SJCRH).  Then she concluded her training at Johns Hopkins in 2015 in concurrent pediatric neuro-oncology and clinical pharmacology fellowships.

Name Position
Caitlin Meeks Postbaccalaureate Fellow (CRTA)
Amelie Vezina Ph.D., M.S. Postdoctoral Fellow (Visiting)